Novo Nordisk reported Q1 2026 on May 6 ↗ with the Wegovy ↗ pill at DKK 2.26 billion (~$354M) in Q1 sales, almost double the DKK 1.16 billion analyst consensus. Total net sales hit DKK 96.82 billion (+24% year-over-year), operating profit climbed 54% to DKK 59.62 billion, and the company tightened full-year guidance from a 5%-13% sales-and-operating-profit decline to a 4%-12% decline at constant exchange rates. NVO US-listed shares rose roughly 6% on the print.
The Wegovy pill numbers worth holding. 1.3 million prescriptions in Q1. More than 2 million cumulative US prescriptions since the January 5 launch. The $354M Q1 sales translates to roughly $272 average revenue per prescription, which sits at the high end of the $25-to-$299 self-pay tier range published with the launch. The disconnect between the 721K IQVIA Q1 prescriptions number ↗ the section flagged ahead of the print and the Novo-reported 1.3 million number is real: IQVIA tracks retail-channel pharmacy fills, while Novo's number includes NovoCare direct-to-consumer pharmacy and the WeightWatchers Med+ telehealth channel that does not flow through retail tracking. The full picture is closer to the 1.3M Novo figure than the 721K IQVIA number.
The injectable franchise. Injectable Wegovy sales rose 12% YoY to DKK 18.2 billion. Ozempic ↗ sales fell 8% YoY but came in above expectations. The combined semaglutide ↗ franchise (oral plus injectable, including Ozempic) generated approximately $4.5 billion in Q1 alone, depending on the kroner-dollar conversion. The guidance tightening, from -5/-13% to -4/-12%, reflects the company's read that volume growth is offsetting price erosion more than the February guidance assumed.
What the print clarifies. The volume-versus-price question the news section raised ahead of the print gets a clean answer: volume won, price compression continued, and the net was substantially better than the February guidance allowed for. Wegovy pill specifically beat consensus by roughly 95%, which is the kind of magnitude that triggers analyst-model rebuilds rather than incremental revisions. The starter-dose 1.5 mg-tier dynamic that drove most of the consumer-acquisition story converted to revenue at a higher rate than the bear case projected, suggesting either substantial dose escalation in Q1 or higher-than-anticipated retention at the starter dose paying $149/month.
The competitive context. Lilly's Q1 print on April 30 ↗ showed Mounjaro ↗ at $8.66 billion and Zepbound ↗ at $4.16 billion globally, with 56% top-line growth. Novo's 24% net sales growth and 54% operating profit growth, on a substantially smaller base, complete the picture of two GLP-1 franchises that are now both producing tier-1 quarterly results despite the price-erosion headwind that has dominated investor conversation for the past nine months. Both companies are now operating well above their respective February guidance ranges. The compounded-GLP-1 supply that backed the bear case has been pulled by the FDA's 503B proposal ↗; the Q1 prints are the first quarterly results to reflect the post-compounding-closure commercial environment.
The platform read. The GLP-1R ↗ target page on peptidemodel anchors the section's metabolic-drug coverage. Wegovy pill is oral semaglutide, the platform's primary peptide reference GLP-1(7-36) amide ↗ modified for oral bioavailability. The Wegovy pill commercial inflection makes the platform's peptide-vs-small-molecule split increasingly load-bearing: Novo's franchise is peptide-only and growing fast; Lilly's franchise is peptide (Mounjaro/Zepbound, tirzepatide ↗) plus small-molecule (Foundayo, orforglipron). Both franchises are growing, but the peptide side is producing the larger and faster-growing revenue base.
What the rest of 2026 has to show. Novo's CagriSema higher-dose Phase 3 trial is now slated for H2 2026 after February's failure to match Zepbound on weight loss. The petrelintide ↗ Phase 3 program with Roche, advanced last week ↗, kicks off in H2 2026. Wegovy HD 7.2 mg launched April 7 with STEP UP 21% weight-loss data (the section is covering separately today). The European Congress on Obesity in Istanbul May 12-15 is the next data inflection point. The Q1 print clears the deck for Novo to focus on data delivery rather than guidance defense for the rest of the year.